Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases

• DOI: 10.18553/jmcp.2022.28.6.657
• Publication Date: 2023-01-13T22:47:23Z
• Authors: Kendra DeBusk; Chiemeka Ike; Nicolas Lindegger; Naomi Schwartz; Andy Surinach; Yutong Liu; Andres Forero-Torres
• Keywords: Real world evidence

BACKGROUND: Among patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC), incidence of brain metastases (BMs) is relatively high and increasing. Despite the unmet need for HER2+ MBC BMs, real-world data on treatment patterns outcomes these are limited. OBJECTIVE: To compare overall survival (OS) among without BMs in United States. METHODS: This was a retrospective cohort study which adults diagnosed between January 1, 2016, May 31, 2019, were identified Flatiron Health electronic health records database. The stratified by presence at diagnosis (baseline) before initiation each line therapy (LOT). Key OS systemic therapy/regimen used within LOT. An adjusted Cox proportional hazards model to evaluate impact OS. RESULTS: Of 1,755 included patients, 173 (9.9%) had baseline. Trastuzumab+ pertuzumab-based regimens most common first- (n = 689, 44.3%) second-line 316, 35.3%) treatments all patients. trastuzumab emtansine third-line regimen 18, 23.4%). Lapatinib-based more frequently but less than 20% any Median 22.3 37.3 months baseline, respectively. Patients higher risk death compared (HR, 3.2; 95% CI 2.6-3.8). CONCLUSIONS: associated an increased mortality MBC. Further studies needed extent novel therapies address BMs. DISCLOSURES: funded Seagen Inc. Andres Forero-Torres employee owns stock Kendra DeBusk Roche. Andy Surinach Yutong Liu employees Genesis Research, received funding from connection this study. At time study, Chimeka Ike Nicolas Lindegger Inc., International GmbH, Naomi Schwartz paid consultant Inc.; she currently